戻る

Lilly’s Jaypirca receives FDA expansion for certain untreated CLL/SLL patients

  • Lilly’s Jaypirca received an expanded indication for certain previously untreated CLL/SLL patients.
  • Jaypirca is described as the first and only approved non-covalent BTK inhibitor.
  • The U.S. FDA granted the expanded indication for Jaypirca (pirtobrutinib).

Eli Lilly’s Jaypirca (pirtobrutinib) received an expanded indication from the U.S. FDA (U.S. drug regulator) for certain patients with previously untreated CLL/SLL. The drug is described as the first and only approved non-covalent BTK inhibitor, a medicine designed to block Bruton’s tyrosine kinase without forming a permanent bond.

当サイトの情報はAIを用いて生成されており、正確性を保証するものではありません。 参考情報としてご活用ください。